New studies reveal predictors for avoidable RA hospitalizations, PsA transition in psoriasis & the impact of neighborhood on childhood lupus.
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. did not observe an increased incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase (JAK) inhibitors compared with those treated with other biologic disease-modifying anti-rheumatic drugs. Their findings support similar cardiovascular risk profiles for JAK and tumor necrosis factor inhibitors.
Preventive Strategies, Novel Treatments & More
Dr. Diane van der Woude reviewed provided a detailed review of the latest research on rheumatoid arthritis, addressing findings on disease prevention, supplements, novel treatments and much more.
The Rheumatic Dangers of Wildfire Smoke
A recent study in A&R identifies an association between air pollutants, including fire smoke particulate matter, & both rheumatoid arthritis (RA) & RA-associated interstitial lung disease.
Positive Week 12 Results for Rosnilimab in Patients with RA
Early study results demonstrate that rosnilimab may be safe and effective for patients with rheumatoid arthritis, reducing the signs and symptoms of RA by week 12 and achieving important primary and secondary study end points.
3 AC&R Study Summaries: SLE Mortality Risk, Heart Failure & RA, & a Phone-Based Walking Program
Risk of Mortality from SLE By Ansaam Daoud, MD, Loai Dweik, MD, & Omer Pamuk, MD Why was this study done? Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant mortality, particularly affecting racial and ethnic minorities. This study aimed to assess national SLE mortality trends over the past two decades, stratified by…
RA: How High Is the Toll?
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.
Cardiovascular & Cancer Risk Factors with JAK Inhibitors
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.
Is Intestinal Dysbiosis Associated with RA?
This study affirms that dysbiosis is a feature of rheumatoid arthritis (RA) and suggests that specific therapies may differentially modulate the gastrointestinal microbiota in RA.
What the Joints Say: Challenges of Tender & Swollen Joint Count Differences
In a new study published in ACR Open Rheumatology, researchers evaluated the impact of tender-swollen joint difference on functional outcomes in early RA and whether associations vary by joint size.
- 1
- 2
- 3
- 4
- Next Page »